kinases becomes activated via a novel synergy between IAP signaling and shear-stress, suggesting that tyrosine kinase activation in the SS RBC is required for IAP-stimulated adhesion under flow conditions. These results therefore identify the SS RBC as a signal-transducing cell and document a new paradigm for the regulation of SS RBC adhesion in the vasculature. Antibodies against IAP, B6H12, and1F7, were generous gifts from Eric Brown (University of CaliforniaSan Francisco, San Francisco, California, USA). The TGF-β neutralizing mAb was purchased from Chemicon International (Temecula, California, USA). Recombinant TGF-β was purchased from Serotec Inc. (Raleigh, North Carolina, USA). Initially, TSP peptides 4N1K (kRFYVVMWKk) and control 4NGG (kRFYGGMWKk) were provided by William Frazier (Washington University, St. Louis, Missouri, USA) (21) . These peptides were also synthesized and HPLCpurified by the University of North Carolina-Chapel Hill Protein Chemistry Laboratory. Pertussis toxin, piceatannol, and genistein were obtained from Calbiochem-Novabiochem Corp.
Methods

Reagents
RBC preparation. SS RBCs were obtained from homozygous SCD patients with informed consent during clinic visits to the University of North Carolina Comprehensive Sickle Cell Center or obtained from healthy controls. All blood samples were drawn by venipuncture into 0.13 M sodium citrate and processed immediately by centrifugation at 150 g for 15 minutes at ambient temperature to isolate blood cells from plasma and platelets. RBCs were then washed three times in CGS (1.29 mM sodium citrate, 3.33 mM glucose, and 124 mM NaCl [pH = 7.2]). The cells were resuspended in PBS and packed at 400 g for 10 minutes. A 1% hematocrit was then prepared by diluting 30 µl of packed RBCs per 1.5 ml of perfusion media (HBSS supplemented with 0.3% BSA and 20 mM HEPES [pH = 7.4] ). This preparation essentially removed all platelets from the washed RBCs (platelet count < 250 per 3 × 10 8 RBCs) and eliminated most white blood cells (WBCs), although WBC counts varied between preparations. Frequently, we were unable to detect WBCs in our samples by direct examination of stained preparations. On average, less than 0.5% of this preparation were WBCs in all experiments except one, in which 1-2% WBCs were present. To confirm that any WBC contamination did not compound our experimental results, we evaluated the contribution of WBCs at the maximal detected contaminating numbers (the 1-2% range) unless otherwise noted.
WBC preparation. WBCs were prepared by layering diluted buffy coats from separated whole blood over a 1.0770-1.0800 Ficoll-sodium diatrizoate solution. The layers were then spun at 400 g for 25 minutes. WBCs were collected, washed in PBS, and resuspended at appropriate concentrations in perfusion media.
Flow adhesion assay and protein immobilization. The flow adhesion system used for this study was designed to mimic blood flow through postcapillary venules, as described previously (5) . Briefly, purified TSP (1.5 µg) in perfusion media was immobilized onto identical wells formed by a silicon gasket in a 35-mm polystyrene culture dish by incubating for 2 hours at 37°C. A 1% hematocrit solution (1.5 ml) was flowed over the wells at a rate of 1.0 ml/min and constant shear stress of 1 dyne/cm 2 . After a wash period of approximately 4 minutes, the number of adherent cells from four representative areas of the well was counted by direct light microscopy. The counted cells were then averaged and presented as adherent cells per square millimeter. Any occasional adherent WBC was not included in the analysis.
SS RBC static adhesion assay. The static adhesion assay used for this study is based on an ATP monitoring system, ATP-Lite (Packard, Groningen, The Netherlands). Microtiter plates (Becton Dickinson, Franklin Lakes, New Jersey, USA) were coated with 1.5 µg TSP for 2 hours at 37°C then blocked with 0.3% BSA for 30 minutes at 37°C. SS RBCs (3 × 10 6 ) or WBCs (6 × 10 4 ) were added to each well and incubated for 2 hours at 37°C. Adherent cells were washed four times, and remaining SS RBCs or WBCs were treated with ATP-Lite for luminescence measurement in a microtiter plate reader (TopCount; Packard Instrument Co., Meriden, Connecticut, USA). Under these conditions no platelet adhesion was observed. All results were verified by direct counting of the SS RBCs (positively identified by Wright/Giemsa staining) by light microscopy (see Figure 3a) with the minimal contaminating WBC ATP subtracted out.
RBC lysis and Western blotting. Cells were lysed for 20 minutes in ice-cold lysis buffer containing 1% Triton X-100, 50 mM HEPES (pH 7.4), 137 mM NaCl, 500 µM EGTA, 100 mM NaVO 3 , 100 mM NaF, and 1X Protease Inhibitor Cocktail Set III (Calbiochem-Novabiochem Corp.). The Triton X-100 soluble fraction was incubated overnight at 4°C with either the antiphosphotyrosine antibody PY20 or PY99 (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) at 2 µg/ml final concentration followed by incubation (1 hour) with protein G Sepharose beads. Immunoprecipitated proteins were washed three times in lysis buffer, reduced according to the method of Laemmli (33) , loaded on 4-20% SDS-PAGE, transferred to PVDF membrane (Millipore), and blotted with 4G10 anti-phosphotyrosine mAb (Transduction Laboratories, Lexington, Kentucky, USA).
Statistics. The significance of any differences for all treatments studied was determined using a two-tailed Student's t test. Unless otherwise noted, P < 0.001.
Results
To evaluate the potential of SS RBCs to become more adhesive in response to agonist-induced signaling, we evaluated the ability of a known ligand and agonist for IAP, soluble TSP, to promote SS RBC adhesion under relevant flow conditions. Freshly drawn, washed human SS RBCs were preincubated (30 minutes at 37°C) with soluble TSP at concentrations reported to be present in the plasma of SCD patients (20) (Figure 1a , inset) and flowed over immobilized TSP under conditions that mimics shear stress and flow in postcapillary venules (5) . Soluble TSP increased SS RBC adhesion to immobilized TSP up to sixfold that of basal SS RBC adhesion observed in the absence of soluble TSP (Figure 1a ). This activation of adhesion cannot be contributed to contaminating TGF-β that copurifies with TSP; we still observed increased SS RBC adhesion in response to soluble TSP that was preincubated with maximal concentrations of a neutralizing TGF-β mAb (data not shown). Furthermore, purified, recombinant TGF-β had no effect on SS RBC adhesion to TSP under flow conditions (data not shown). These results indicate a potentiating effect of soluble TSP on SS RBC adhesion to immobilized TSP. Because of this promotion, rather than inhibition, of SS RBC adhesion to immobilized TSP by soluble TSP, it appears that soluble TSP binds to SS RBCs by a mechanism distinct from that of immobilized TSP, and potentially activates SS RBCs.
Because IAP is an agonist receptor in response to TSP on other cells, we evaluated its role as an agonist receptor for soluble TSP on SS RBCs with the IAP-function blocking mAb 1F7 (34) . We found that TSP-stimulated adhesion was completely blocked by 1F7 (1 µg/ml) (Figure 1c ), but not by an isotype-matched control antibody (data not shown). These results suggest that IAP is essential for the response to soluble TSP under these conditions.
To confirm that IAP occupancy can promote SS RBC adhesion to immobilized TSP, we preincubated SS RBCs with an IAP-specific agonist peptide derived from TSP, termed 4N1K (21, 35) . We had previously determined that this peptide could support SS RBC adhesion under flow conditions and that IAP under basal flow conditions is an adhesion receptor on SS RBCs for TSP (26) . However, under identical shear conditions as above, the , whereas the 4NGG control peptide (kRFYGGMWKk) has no effect on SS RBC adhesion to immobilized TSP under flow (triangles). Data were normalized from six independent patient samples and are shown as ± SD. 4N1K treatment has no effect on AA RBC adhesion (circles, n = 3 donors). We next investigated the effects of another IAP-specific mAb, B6H12, on SS RBC adhesion to immobilized TSP. B6H12 blocks ligand binding to IAP on most cells (22, 34) , but stimulates IAP signaling in at least one cell type (23) . We observed that B6H12 increased SS RBC adhesion to immobilized TSP under shear conditions (Figure 2a ). This result further supports a role for IAP as an agonist receptor on SS RBCs that activates adhesion.
To determine the contribution of shear stress to TSP agonist-induced adhesion, we examined SS RBC adhesion to immobilized TSP in the absence of shear. For this purpose, a static adhesion assay was designed in a 96-well format. We found two immediate differences between sickle cell adhesion under shear versus static conditions. First, although B6H12 stimulated SS RBC adhesion in the flow adhesion assay (Figure 2a) , treatment with this mAb, but not an isotype-matched control mAb, completely blocked SS RBC adhesion to TSP in the static adhesion assay (Figure 2b) . Second, although the 4N1K agonist peptide stimulated sickle cell adhesion to immobilized TSP under flow ( Figure  1b) , SS RBC treatment with the 4N1K peptide (squares), but not the control 4NGG peptide (ovals), completely inhibited sickle cell adhesion to immobilized TSP in the static assay (Figure 2c ). These results suggest that under static conditions, IAP is a major sickle cell adhesion receptor for immobilized TSP. These data also suggest that shear stress provides an essential component to the activation of SS RBC adhesion that occurs in response to 4N1K, soluble TSP or B6H12 binding to IAP on the SS RBC. Thus, although IAP clearly appears to be a major static adhesion receptor for immobilized TSP, our results also suggest that IAP can function as an agonist receptor that, under relevant flow conditions, potentially activates sheardependent signal transduction in the SS RBCs.
We next tested our hypothesis that IAP activates a signaling pathway in SS RBCs that, under flow conditions, promotes adhesion to immobilized TSP. In
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The platelets and smooth muscle cells, IAP functionally couples to, and signals via, the large G protein G i (22, 36) . In addition, several nonreceptor tyrosine kinases have been implicated in IAP signaling (22, 23) . To examine potential IAP signaling in SS RBCs, we pretreated SS RBCs with the G i inhibitor pertussis toxin (1 µg/ml, 30 minutes) and stimulated the cells with the 4N1K agonist peptide. Pertussis toxin treatment almost completely blocked the 4N1K-stimulated component of SS RBC adhesion to immobilized TSP (Figure 3a) , but had no effect on basal, nonagonist-stimulated adhesion to TSP (data not shown), suggesting a role for G i activation downstream of IAP in SS RBCs. Pertussis toxin also blocked soluble TSP-stimulated adhesion to immobilized TSP, but by about 50% (Figure 3b) , suggesting that soluble TSP may act via multiple signaling pathways in the SS RBCs (Figure 3b ). Consistent with a role for tyrosine kinase activity in IAP signaling, the tyrosine kinase inhibitor piceatannol (30 µg/ml) also blocked 4N1K-stimulated SS RBC adhesion to immobilized TSP under flow conditions. Treatment with genistein (260 µM), another tyrosine kinase inhibitor, also partially blocked the SS RBC response to the 4N1K peptide (Figure 3a ), but completely blocked the response to soluble TSP (Figure 3b ), further implying that tyrosine kinase become activated as a result of 4N1K or TSP stimulation. Neither inhibitor had any effect on basal SS RBC adhesion (data not shown). These results indicate that 4N1K-induced IAP signaling in SS RBCs is similar to that in other agonistregulated cells and involves the activation of large G proteins and tyrosine kinases. Another potent inducer of intracellular signaling in several cell types is the shear stress that results from exposure of cells to blood flow. Endothelial cells exposed to shear exhibit marked differences in receptor expression, differentiation, and cell signaling (37, 38) . Likewise, platelets exposed to high shear arterial blood flow can spontaneously activate (39) and adhere to the blood vessel wall by mechanisms distinct from platelets under slower venous flow conditions (40, 41) .
To explore further the shear-induced component of IAP signaling in SS RBCs, we exposed nonstimulated SS RBCs to a 2-minute pulse of shear identical to that present in the flow adhesion assay. The cells were lysed immediately after shear and were analyzed by immunoprecipitation of tyrosine-phosphorylated proteins followed by SDS-PAGE and immunoblotting. As shown in a representative blot (Figure 4a) , exposure of SS RBCs to shear alone induced both the phosphorylation and dephosphorylation of several protein bands relative to SS RBCs under static conditions. Most notably, proteins migrating at approximately 100 and 70 kDa became markedly phosphorylated, whereas proteins migrating at approximately 45 and 27 kDa lost phosphotyrosine content. These results show that both shear-dependent tyrosine phosphorylation and dephosphorylation of proteins occur in the SS RBCs and further support a role for shear stress in the activation of SS RBC adhesion. To investigate the combined effects of IAP-mediated signaling and shear on cellular protein phospho-tyrosine content, we stimulated SS RBCs with the 4N1K agonist peptide (100 µM), exposed the cells to shear stress, and analyzed phosphotyrosine content as above. The combination of agonist peptide and shear stress further increased the tyrosine phosphorylation of the 100-and 70-kDa bands and caused the appearance of several additional bands (Figure 4b, lane 3) . This increase in tyrosine phosphorylation of the 100-and 70-kDa bands was completely blocked by pretreatment of SS RBCs with piceatannol ( Figure 4c, lane 2) . Examination of the phosphotyrosine content of an overestimate of contaminating numbers of purified WBCs (200,000 cells) or platelets (50,000) under identical treatment conditions indicated a lack of detectable tyrosine phosphorylation in these cells, even under shear stress coupled with 4N1K stimulation (Figure 4b, lanes 1 and 2) . These data indicate that the change in protein tyrosine phosphorylation from both shear stress and 4N1K peptide stimulation occurs in the SS RBCs. Furthermore, treatment of SS RBCs with piceatannol blocked 4N1K-induced tyrosine phosphorylation (Figure 4c , lane 2), consistent with this inhibitor's ability to block IAPstimulated adhesion. These results demonstrate that the SS RBC is initiating cell signaling in response to changes in its environment that can result in increased adhesion of these cells.
Interestingly, the 4N1K peptide can induce moderate tyrosine phosphorylation of the 100-and 70-kDa bands in the absence of shear (data not shown). Furthermore, immobilized TSP also induces tyrosine phosphorylation of these protein bands under static conditions (data not shown). Yet, the presence of either agonist alone fails to activate SS RBC adhesion in the absence of shear. These results further indicate that full IAP stimulation of SS RBC adhesion absolutely requires a novel synergy between shear stress and receptor ligation. Additionally, AA RBCs, which failed to functionally respond to agonist peptide stimulation (Figure 1b) , also exhibited almost no change in amounts of tyrosine phosphorylated proteins under any of the tested conditions (Figure 4d ), again suggesting an SS RBC-specific response to IAP stimulation and shear.
Given that reticulocytes may retain several signaling pathways and molecules that are lost upon normal RBC maturation (42), we hypothesized that it was these young RBCs that were mounting the signaling response to IAP. Therefore, we separated SS RBCs on an arabinogalactan gradient (26) and tested the ability of the lowdensity (reticulocyte-enriched) and high-density (reticulocyte-depleted) fractions to respond to 4N1K stimulation under flow conditions. The low-density fraction exhibited a robust response to the 4N1K but not the 4NGG peptide, whereas the reticulocyte-depleted fraction was markedly deficient in response to 4N1K stimulation of adhesion in two separate patients (Figure 5a) . These results strongly suggest that the low-density, reticulocyte-enriched fraction of SS RBCs represents the most reactive population of SS RBCs. Moreover, RBCs from a patient with an idiopathic hemolytic anemia and markedly elevated reticulocyte count (35-40%), but AA hemoglobin, clearly responded to 4N1K agonist peptide or soluble TSP stimulation under flow (Figure 5b ), suggesting that an increased reticulocyte population is sufficient to confer a response to IAP stimulation. Interestingly, this patient's RBCs, unlike SS RBCs, failed to adhere basally to immo-
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The In contrast, when plasma levels of TSP are elevated, as in SCD, we propose that IAP is largely occupied by plasma TSP and unable to participate directly in adhesion to immobilized TSP. However, IAP stimulation by plasma TSP in combination with physiological shear stress, via a G i -and tyrosine kinase-dependent pathway, activates a distinct, yet unidentified, TSP receptor that preferentially recognizes immobilized matrix-or cellassociated TSP (binding site 2). We further propose that site 2 is relatively inaccessible in plasma TSP, thus explaining the marked IAPmediated activation of SS RBCs by soluble TSP, instead of an inhibition of adhesion to immobilized TSP. Finally, we demonstrate that activation of a distinct TSP receptor more than compensates for a loss of direct IAP adhesion to immobilized TSP, therefore promoting overall SS RBC avidity for immobilized TSP. bilized TSP under flow conditions (J.E. Brittain and L.V. Parise, unpublished observations), which might be explained by a physical difference in IAP that we previously noted on SS RBCs (26) . These results further suggest that the more immature RBCs in SCD, and perhaps other anemias, respond to agonist stimulation.
Discussion
In summary, we show an unprecedented role for IAPmediated signaling in sickle erythrocytes and demonstrate a new potential pathological role for this receptor in SCD. We find that in the presence of shear stress, IAP specifically activates SS RBC adhesion to immobilized TSP via a G i , and tyrosine kinase-dependent pathway. Our data suggest that this synergy between IAP and shear leads to the activation of as yet uncharacterized TSP receptors on SS RBCs that preferentially bind to immobilized, or matrix TSP, in the presence of soluble TSP or the 4N1K agonist peptide (43) .
In a previous study, we identified IAP as a TSP receptor on SS RBCs that mediates a significant amount of the basal adhesion of these cells to immobilized platelet TSPs under relevant flow conditions (26) . As illustrated in a model (Figure 6 ), our data also suggest that with elevated plasma TSP as in SCD, IAP is largely occupied by soluble TSP, which activates a distinct TSP receptor(s) that efficiently binds to an adhesive, exposed site on TSP (binding site 2) when TSP is constrained on a solid-phase support. We predict that such conformations of TSP would be presented to SS RBCs in flowing blood either as exposed matrix TSP or as plasma TSP bound to the endothelium. The dependence of TSPinduced signaling on shear stress further suggests that the resulting adhesiveness of SS RBCs may be most relevant in the initiation of vaso-occlusion in flowing blood, which would serve to compromise blood flow, induce turbulence, and slow transit through the vasculature. In contrast, under largely static conditions, which would be expected behind a vaso-occlusion, our results suggest that IAP may function largely as an adhesion receptor for TSP bound to various sites in the vasculature, ultimately propagating vaso-occlusion. Therefore, we believe that IAP is a viable, twofold therapeutic target whose disruption could decrease the frequency and duration of vaso-occlusion in SCD.
It is intriguing that while SS RBCs respond to shear and IAP signaling in SCD, normal peripheral RBCs, which express IAP and are constitutively exposed to shear in vivo, remain nonresponsive under any of our studied conditions. The rapid clearance of SS RBCs leads to an increased reticulocyte population and younger average age of all circulating RBCs in SCD patients. Our data suggest that these young peripheral cells retain signaling molecules and pathways lost in more mature RBCs and, as a result, are the most responsive to IAP-induced SS RBC signaling. In fact, peripheral reticulocytes are rare in normal peripheral blood, and the minimal numbers of these cells in normal donors could account for the lack of response of normal patients. Therefore, our data also suggest that several pathological anemias may render patients vulnerable to increased reticulocyte adhesion as a result of signal transduction in the cells.
We propose that SCD patients would be particularly vulnerable to TSP-stimulated RBC adhesion, due to both elevated plasma levels of TSP and increased reticulocyte counts (1, 20) . Under shear conditions, soluble TSP, present presumably in multiple conformations in the plasma of SCD patients, could induce IAP-activated sickle cell adhesion to TSP bound to endothelial cells or exposed in the subendothelial matrix in vivo, dramatically promoting vaso-occlusion. In fact, a study by Kumar et al. in which α4β1-mediated SS RBC adhesion to endothelial cells appeared to be upregulated by IL-8 or PMA (44) , is consistent with our results that signal transduction in SS RBCs can be a basis for increasing sickle cell adhesion. Our data demonstrate, however, that IAP-mediated signaling in combination with shear-stress increases adhesiveness of SS RBCs, thus providing a new paradigm of sickle cell adhesion.
Our data thus far suggest that SS RBCs may be capable of activating multiple signaling pathways, as 4N1K-and TSP-stimulated pathways are affected in a similar but not identical manner to signaling inhibitors. SS RBCs express at least one additional TSP receptor, GPIV or CD36, a known signaling receptor on other cells that may affect the TSP-but not 4N1K-induced SS RBC signaling. Also, the points at which shear and IAP signaling impinge in SS RBCs, and the identity of the IAPactivated TSP receptor on SS RBCs, are unknown but currently under investigation. Identification of each of the signaling pathways stimulated by IAP, shear and/or soluble TSP increases the likelihood that additional therapeutic targets will be identified to downregulate SS RBC adhesion and vaso-occlusive crises in SCD.
